During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …

During the past decade, treatment strategies for patients with advanced prostate cancer
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …

177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …

ABSTRACT The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC)
Expert Panel identified and reviewed the available evidence for the ten most important areas …

Aims There is a controversy as to the relative efficacy of 177 Lu prostate specific membrane
antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with …

Purpose Radioligand therapies targeting prostate-specific membrane antigen (PSMA) have
been established for the treatment of metastasized castration-resistant prostate cancer …

The treatment landscape of advanced prostate cancer has widely expanded over the past
years with androgen receptor signaling inhibitors (ARSIs) and taxane chemotherapy moving …

Significant progress has been made in the understanding of the underlying cancer biology
of castration‐resistant prostate cancer (CRPC) with the androgen receptor (AR) signalling …

Background Enzalutamide and abiraterone acetate plus prednisone, which target the
androgen receptor axis, have expanded the treatment of advanced prostate cancer …

Background The increased use of the androgen receptor axis-targeted (ARAT) agents
abiraterone and enzalutamide in first-and second-line treatment of metastatic castration …